Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Kswdeluxon Dec 28, 2022 2:40pm
178 Views
Post# 35194051

RE:RE:RE:RE:RE:What just happened

RE:RE:RE:RE:RE:What just happened

Lesalpes29 wrote:
itntdf wrote: would prefer they not release sidney powell at this time.
Bigger volume but not that crazy selling! Manipulation I think. The story didn't since change last week. Respirons and let the storm pass.


 

The market is generally slow through the holidays. Meaning not the normal volume of buyers.

The bigger volume in the downwards direction is only due to a smaller volume of daily manipulators doing the trading through these low days taking out STOP SELLS. There is often a large volume of stock avalable through STOP SELLS if you can time taking out the STOP SELLS with a slow day, meaning a day with less traders. You would only do this if you felt there is upside to the stock.

STOP SELLS are not shareholders wanting to sell, just locking in their profit. If their stock is sold by a STOP SELL they hope to buy back in low. Just protecting profit.

With the end of the year only a few days away, and the tax loss period over, those that sold for tax losses will most often buy back in creating more demand. SP will go up.

With the expectation of Accelarated Approval coming in Q1 or Q2 and the major media event planned for April/May I think we will start to see a climbing SP until the major media event.

In the mean time, I am not ruling out a Panc Accelarated Approval designation within the next few weeks, months, but before the major media event with a move by Roche, all before PFE's 90 days are up, when ever that is. But then again, maybe they are letting the panc results mature as well for final data there. If nothing else, the major media event will be a big day for ONC.

I am expecting that we will get a status update as to PFE's 90 period with the 4th quarter financial results.

Cheers everyone!

2023 WILL be an exciting year.

 

<< Previous
Bullboard Posts
Next >>